Xilio Therapeutics, Inc. (XLO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Xilio Therapeutics, Inc. (XLO) closed at USD 8.90 on 2026-10-14, a change of -22.5 % over the past year, with a market capitalization of USD 59.35M.

Xilio Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Xilio Therapeutics, Inc. key figures

Previous close

USD 8.90 (2026-10-14)

1-year change

-22.5 %

Market cap

USD 59.35M

Enterprise value

USD -70.38M

P/E ratio (trailing)

-15.03

P/E ratio (forward)

-15.55

EPS (trailing)

-0.60

EPS (forward)

-0.58

PEG ratio

n/a

Price to book

1.16

Revenue growth

131.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

38.99

Employees

76

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Xilio Therapeutics, Inc. and compare it with other stocks.